Ipamorelin + CJC-1295 Blend.
The most widely used growth hormone stack in clinical longevity practice. Ipamorelin activates the ghrelin receptor; CJC-1295 (no DAC) activates the GHRH receptor — together producing a synergistic GH pulse substantially larger than either compound alone, with a highly selective safety profile.
- Compounds
- Ipamorelin + CJC-1295 (No DAC)
- Stack Type
- GHRP + GHRH synergistic pulse
- Mechanism
- Dual pituitary receptor activation
- Class
- GH secretagogue stack
- Status (UAE)
- Research-grade compounding
Alone, a flicker. Together, a flood.
Academic research establishes that GHRH and GHRP receptor co-activation produces synergistic GH release — far exceeding the additive effects of either pathway alone.
Ipamorelin (Novo Nordisk, NNC 26-0161) emerges as the preferred GHRP partner: uniquely selective for GH with no cortisol or prolactin spikes seen in GHRP-2/6.
CJC-1295 no DAC (Mod GRF 1-29) provides the GHRH pulse without receptor down-regulation; combined with IPA at bedtime it is now the most-prescribed GH stack globally.
GHRH Meets GHRP, The Classic Pulse.
Aib-His-D-2Nal-D-Phe-Lys-NH₂
C₃₈H₄₉N₉O₅ · MW 711 Da · t½ ~2h
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Nle-Ser-Arg
C₁₅₂H₂₅₂N₄₄O₄₂S · MW 3367 Da · t½ ~30 min
The clinic ran ahead of the trial.
Synergy is mechanistically sound. Human combination trial data remains thin.
- Dual-receptor GH amplification
- IPA: no cortisol/prolactin spike
- CJC: no receptor desensitisation
- IGF-1 elevation confirmed
- GH axis feedback preserved
- Body composition improvement
- Sleep quality enhancement
- Recovery acceleration
- Visceral fat reduction
- Anti-aging via GH restoration
- Muscle gain in healthy adults
- Cognitive enhancement
- Athletic performance
Sign in to view the full research brief.
Mechanism deep-dive and research dosing protocols — available to registered researchers. It's free and takes under a minute.
Widely prescribed. Barely trialled.
In the UAE, research-grade peptides occupy a defined regulatory category distinct from licensed medicines. Compounds sold under this classification — including those offered by Dubai Peptides — are intended exclusively for qualified research applications, not for human administration.
Ipamorelin reached Phase I/II human trials under Novo Nordisk (NNC 26-0161) in the late 1990s but was not developed commercially. CJC-1295 no DAC (Modified GRF 1-29) has not completed regulatory review in any jurisdiction. The IPA/CJC combination has no registered clinical trial, yet is among the most prescribed peptide stacks in longevity clinics globally — a textbook case of clinical practice outpacing evidence.
Academic work establishes GHRP + GHRH supra-additive GH release; ipamorelin identified as uniquely selective GHRP with clean safety profile.
CJC-1295 no DAC popularised for shorter action without desensitisation; IPA/CJC becomes the standard GH secretagogue stack in longevity medicine.
Most widely prescribed peptide GH stack worldwide; a compounding market for this combination exists in the UAE, operating outside the research-use classification this platform follows.